UNSPSC 51422502: Acrocinonide

This classification denotes a therapeutic glucocorticoid with the molecular formula C24H29FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 67N58AU0IZ, chemically known as 9-fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acrolein but generally known as acrocinonide, which bears US NIH Compound Identifier 176868. European Medicines Agency schedules Acrocinonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05253MIG.

UNSPSC 51422502 Acrocinonide is a Commodity code that in recent state and local procurement does not reflect purchases of the pharmaceutical compound itself, but rather naloxone (an opioid-reversal medication) and associated drug deactivation systems procured by public health and human services agencies. State and local governments under this code are buying naloxone units and safe drug deactivation equipment for community health programs, emergency response, and pharmaceutical waste management—products that reflect the public health mandate rather than the narrower chemical category the code nominally describes. Issuing bodies include county health departments and state health and human services commissions. Seminole County, Florida, and the Texas Health and Human Services Commission represent the current buyer base evident in recent solicitations.

Procurement activity under this code concentrates in Florida and Texas. Seminole County released IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring how vendors could manage direct pharmaceutical contracting outside traditional pharmacy benefit manager and group purchasing organization channels. The mismatch between the code's chemical name and the actual work being solicited—naloxone procurement and pharmacy program design rather than acrocinonide itself—suggests this code may be mislabeled in recent state and local systems, and firms should verify code accuracy before pursuing opportunities tagged under it.